ERYTHROPOIETIN ( DrugBank: Erythropoietin )

9 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	4
6	パーキンソン病	1
13	多発性硬化症／視神経脊髄炎	4
18	脊髄小脳変性症（多系統萎縮症を除く。）	2
22	もやもや病	2
47	バージャー病	1
70	広範脊柱管狭窄症	1
95	自己免疫性肝炎	1
96	クローン病	1

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03835507 (ClinicalTrials.gov)	June 20, 2016	8/8/2018	Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis	Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: recombinant human erythropoietin(rhEPO)	Hanyang University Seoul Hospital	NULL	Recruiting	25 Years	80 Years	All	64	Phase 1/Phase 2	Korea, Republic of
2	EUCTR2011-001329-26-IT (EUCTR)	03/08/2011	17/11/2011	Erythropoietin in Amyotrophic Lateral Sclerosis: a study to identify the best dose and the optimal route of administration and evaluate the safety	ErythroPOietin in ALS: a Study of dose-finding and Safety - EPOSS2010	Amyotrophic Lateral Sclerosis MedDRA version: 14.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: EPREX*1SIR 40000UI/ML 1ML INN or Proposed INN: ERYTHROPOIETIN	ISTITUTO NEUROLOGICO CARLO BESTA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40		Italy
3	EUCTR2009-016066-91-IT (EUCTR)	10/03/2010	17/11/2009	SAFETY AND EFFICACY OF ERYTHROPOIETIN IN AMYOTROPHIC LATERAL SCLEROSIS: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL - ND	SAFETY AND EFFICACY OF ERYTHROPOIETIN IN AMYOTROPHIC LATERAL SCLEROSIS: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL - ND	ALS MedDRA version: 9.1;Level: SOC;Classification code 10029205	Trade Name: EPREX*1SIR 40000UI/ML 1ML INN or Proposed INN: Erythropoietin	ISTITUTO NEUROLOGICO CARLO BESTA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
4	EUCTR2005-005873-31-IT (EUCTR)	01/08/2005	14/03/2006	A randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of Erytropoietin administered by iv route as add-on treatment in patients affected by Amyotrophic Lateral Sclerosis ALS - ND	A randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of Erytropoietin administered by iv route as add-on treatment in patients affected by Amyotrophic Lateral Sclerosis ALS - ND	Amiotrophic Lateral Sclerosis MedDRA version: 6.1;Level: PT;Classification code 10002026	Trade Name: EPREX IV SC 1FL 1ML 40000 UI INN or Proposed INN: Erythropoietin	ISTITUTO NEUROLOGICO CARLO BESTA	NULL	Not Recruiting			Female: yes Male: yes	20		Italy

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01010802 (ClinicalTrials.gov)	August 2008	8/11/2009	Safety Study of Erythropoietin (EPO) in Parkinson's Disease	Phase 1 Study of Recombinant Human Erythropoietin (rhEPO) in Parkinson's Disease (PD)	Parkinson Disease	Drug: Erythropoietin human recombinant (EPOrh)	International Center for Neurological Restoration, Cuba	Centro de Immunologia Molecular, Cuba	Completed	45 Years	75 Years	All	10	Phase 1	Cuba

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01144117 (ClinicalTrials.gov)	November 2009	7/6/2010	The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis	Double Blind, Placebo-controlled Study to Assess the Effects of Erythropoietin on Clinical Disability and Brain Pathology as Shown by Magnetic Resonance Imaging in Patients With Progressive Multiple Sclerosis	Multiple Sclerosis (Primary or Secondary Progressive Phase).	Drug: Erythropoietin	Rigshospitalet, Denmark	Danish Research Centre for Magnetic Resonance	Recruiting	19 Years	60 Years	Both	56	Phase 2	Denmark
2	EUCTR2009-011516-37-DK (EUCTR)	29/05/2009	15/05/2009	Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multiple sclerosis - EPO-ProgMS	Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multiple sclerosis - EPO-ProgMS	Multiple Sclerosis, with primary and secondary progressive courses. MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis	Trade Name: NeoRecormon INN or Proposed INN: Solu-Medrol Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE	Danish Multiple Sclerosis Research Centre	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Denmark
3	EUCTR2008-005125-11-GB (EUCTR)	19/12/2008	07/01/2009	A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis.	A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis.	Primary progressive multiple sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063401;Term: Primary progressive multiple sclerosis	Trade Name: Neorecormon Product Name: Recombinant Human Erythropoietin Product Code: rhEPO INN or Proposed INN: epoetin beta	Walton Centre for Neurology and Neurosurgery	NULL	Not Recruiting			Female: yes Male: yes			United Kingdom
4	EUCTR2005-005592-14-DE (EUCTR)	27/07/2006	12/05/2006	Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTECT) - Vision Protect	Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTECT) - Vision Protect	Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents one of the most common and frequently the first clinical manifestation of MS. Optic neuritis is mainly characterized by a subacute loss of vision.	Trade Name: Erypo/Erypo FS Product Name: Erypo/Erypo FS INN or Proposed INN: Epoetin alfa Other descriptive name: Epo Trade Name: Urbason solubile forte 1000mg Product Name: Methylprednisolone INN or Proposed INN: Methylprednisolon-21-hydrogensuccinat, Natriumsalz	IFSgGmbH, Institute for clinical research	NULL	Not Recruiting			Female: yes Male: yes			Germany

18. 脊髄小脳変性症（多系統萎縮症を除く。）

臨床試験数 : 76 / 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-000040-13-AT (EUCTR)	11/02/2009	27/01/2009	Effects of recombinant human Erythropoietin on circulating and intramuscular endothelial progenitor cells, neovascularisation and oxidative metabolism of skeletal muscle in Friedreich’s Ataxia	Effects of recombinant human Erythropoietin on circulating and intramuscular endothelial progenitor cells, neovascularisation and oxidative metabolism of skeletal muscle in Friedreich’s Ataxia	Friedreich's ataxia (FRDA) is the most common autosomal recessive neurodegenerativ disease (1:50 000) affecting the central and peripheral nervous system. Extraneural organs are also affected during the course of the disease as a significant proportian of patients develop cardiomyopathy or diabetes. FRDA is caused by a GAA triplet expansion in the FRDA gene on chromosome 9q13 resulting in a loss of function of the gene product Frataxin.	Trade Name: Neorecormon Product Name: Neorecormon Product Code: EU1/97/031-032 INN or Proposed INN: H-116PI-DE.pdf Other descriptive name: Epoeitin beta	Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie	NULL	Not Recruiting			Female: yes Male: yes	7	Phase 2	Austria
2	EUCTR2007-003357-85-IT (EUCTR)	10/10/2007	09/11/2007	Randomized placebo-controlled double-blind trial to assess safety and efficacy of erythropoietin in adult patients with Friedreich's ataxia (a pilot study) - ND	Randomized placebo-controlled double-blind trial to assess safety and efficacy of erythropoietin in adult patients with Friedreich's ataxia (a pilot study) - ND	Friedreich ataxia (FRDA) is a rare autosomal recessive neurodegenerative disorder caused a mutation in the FXN gene, which encodes a protein named frataxin. As a result of the mutation, frataxin is quantitatively reduced but qualitatively normal. Thus, any pharmacological agent able to increase frataxin intracellular levels would have a great therapeutic relevance. MedDRA version: 6.1;Level: PT;Classification code 10003591	Trade Name: EPREX*1FL 40000UI/ML 1ML INN or Proposed INN: Erythropoietin Other descriptive name: Erythropoietin	ISTITUTO NEUROLOGICO CARLO BESTA	NULL	Not Recruiting			Female: yes Male: yes			Italy

22. もやもや病

臨床試験数 : 17 / 薬物数 : 22 - (DrugBank : 17) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 45

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03882060 (ClinicalTrials.gov)	April 8, 2019	12/3/2019	Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients	The Effect of Recombinant Human Erythropoietin on the Postoperative Neurologic Outcome in Pediatric Moyamoya Disease Patients - A Double Blind Randomized Controlled Trial	Moyamoya Disease;Pediatrics;Cerebrovascular Disorders	Drug: erythropoietin;Drug: Normal saline	Seoul National University Hospital	NULL	Active, not recruiting	N/A	18 Years	All	60	N/A	Korea, Republic of
2	NCT03162588 (ClinicalTrials.gov)	May 1, 2010	18/5/2017	Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya	Feasibility Study of Multiple Burrhole Therapy Combined With Intravenous Erythropoietin Pretreatment for Unstable Moyamoya	Ischemic Attack;Ischemic Stroke;Moyamoya Disease;Burr Hole;Angiogenesis	Drug: erythropoietin	Ajou University School of Medicine	NULL	Completed	16 Years	N/A	All	37	Phase 1/Phase 2	Korea, Republic of

47. バージャー病

臨床試験数 : 9 / 薬物数 : 14 - (DrugBank : 7) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 16

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000021374	2016/03/07	07/03/2016	Ex Vivo Expanded Erythroblast-Transplantation for patient with critical limb ischemia	Ex Vivo Expanded Erythroblast-Transplantation for patient with critical limb ischemia - EVEETA study	Peripheral Arterial Disease (PAD) , Buerger disease, and arteritis associated with collagen diseases (Fontaines stage: III and IV)	1)Autologous Bone Marrow Collection: 40 to 60 ml of bone marrow is collected from iliaccrest under local anaesthesia 14 days before the implantation. 2)Ex vivo expanded immature erythroblasts from autologous bone marrow cells : All procedures are enforced by exclusive technical exparts along the approved protocols in GMP-grade Cell Processing Room established in Bioscience Medical Research Center, Niigata University Medical and Dental Hospital. Mononuclear cells separated from the bone marrow are incubated in a suspension culture in the presence of rh Flt-ligand, rh SCF, rh Thrombopoietin, and culture supplements for 7 days to expand myeloid progenitors. Harvested and washed cells are further cultured in the presence of rh SCF, rh IGF-I, rh Erythropoietin, and culture supplements for additional 7 days to expand immature erythroblasts and macrophages. Cultured cells are finally harvested, washed, suspended in 50 ml of autologous platelet rich plasma, and transferred from the bio clean room to bedside. 3)Transplantation of cultured cell: Aliquots of the 50 ml of cell suspension are intramuscularly injected in 100 points of the ischaemic limb. Daily intramuscular injection of 6000 IU of rh erythropoietin in the same loci follows from day 0 for consecutive 5 days.	EVEETA Study Group	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	11	Not selected	Japan

70. 広範脊柱管狭窄症

臨床試験数 : 95 / 薬物数 : 169 - (DrugBank : 61) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 90

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-INR-17012403	2017-09-01	2017-08-17	Application of erythropoietin in enriched bone marrow stem cells technique to promote bone regeneration	Application of erythropoietin in enriched bone marrow stem cells technique to promote bone regeneration	bone defect, bone non-union and lumber spinal stenosis	treatment group:administer erythropoietin (150U/kg) three to five times via subcutaneous or intravenous injection before operation;controlled group:administer normal saline three times via subcutaneous or intravenous injection before operation;	Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine	NULL	Pending	18	65	Both	treatment group:44;controlled group:44;		China

95. 自己免疫性肝炎

臨床試験数 : 52 / 薬物数 : 68 - (DrugBank : 27) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 111

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03842254 (ClinicalTrials.gov)	January 25, 2019	12/2/2019	Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease	Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease	Autoimmune Hepatitis	Drug: Erythropoietin	Northwestern University	Mount Sinai Hospital, New York;Icahn School of Medicine at Mount Sinai	Completed	18 Years	74 Years	All	6	Early Phase 1	United States

96. クローン病

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01823029 (ClinicalTrials.gov)	November 2012	25/3/2013	Oxidative Stress and Inflammation Caused by Intravenous Iron in Crohn's Disease Patients With Iron Deficiency Anemia		Crohn's Disease	Drug: erythropoietin;Drug: enteral nutrition.;Drug: injection of iron	Jinling Hospital, China	Ministry of Health, China	Completed	18 Years	75 Years	Both	387	N/A	China

先頭へ